Genetic variability and opioid efficacy

Current Anaesthesia and Critical Care

Volumn 18, Issue 3, 2007, Pages 149-156

  Klepstad, Pål ^a,b  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

Analgesics; Genes; Genetic variation; Opioid; Pain

Indexed keywords

ADENINE; ADRENALIN; ALFENTANIL; BETA ARRESTIN; CODEINE; CYTOCHROME P450 2D6; DOPAMINE; ENKEPHALIN; GUANINE; LEVOMETHADONE; MELANOCORTIN 1 RECEPTOR; METHIONINE; MORPHINE; MORPHINE 6 GLUCURONIDE; MU OPIATE RECEPTOR; MULTIDRUG RESISTANCE PROTEIN 1; NARCOTIC ANALGESIC AGENT; NORADRENALIN; OPIATE AGONIST; OPIATE DERIVATIVE; PENTAZOCINE; STAT6 PROTEIN; TRAMADOL; VALINE;

ANALGESIC ACTIVITY; ARTICLE; CANCER PAIN; CLINICAL OBSERVATION; CLINICAL RESEARCH; CONSTIPATION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG RECEPTOR BINDING; GENE MUTATION; GENETIC CODE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; MOLECULAR MECHANICS; NONHUMAN; PAIN; POSTOPERATIVE PAIN; PRIORITY JOURNAL; RESPIRATION DEPRESSION; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT;

EID: 34548430044     PISSN: 09537112     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cacc.2007.06.001     Document Type: Article

References (48)

1. McQuay H.J., Carroll D., Faura C.C., Gavaghan D.J., Hand C.W., and Moore R.A. Oral morphine in cancer pain: influences on morphine and metabolite concentration. Clin Pharmacol Ther 48 3 (1990) 236-244
2. Klepstad P., Kaasa S., Skauge M., and Borchgrevink P.C. Pain intensity and side effects during titration of morphine to cancer patients using a fixed schedule dose escalation. Acta Anaesthesiol Scand 44 6 (2000) 656-664
3. Thirlwell M.P., Sloan P.A., Maroun J.A., Boos G.J., Besner J.G., Stewart J.H., et al. Pharmacokinetics and clinical efficacy of oral morphine solution and controlled-release morphine tablets in cancer patients. Cancer 63 11 Suppl. (1989) 2275-2283
4. Collin E., Poulain P., Gauvain-Piquard A., Petit G., and Pichard-Leandri E. Is disease progression the major factor in morphine 'tolerance' in cancer pain treatment?. Pain 55 3 (1993) 319-326
5. Osborne R., Thompson P., Joel S., Trew D., Patel N., and Slevin M. The analgesic activity of morphine-6-glucuronide. Br J Clin Pharmacol 34 2 (1992) 130-138
6. Klepstad P., Kaasa S., and Borchgrevink P.C. Start of oral morphine to cancer patients: effective serum morphine concentrations and contribution from morphine-6-glucuronide to the analgesia produced by morphine. Eur J Clin Pharmacol 55 10 (2000) 713-719
7. Klepstad P., Borchgrevink P.C., Dale O., Zahlsen K., Aamo T., Fayers P., et al. Routine drug monitoring of serum concentrations of morphine, morphine-3-glucuronide and morphine-6-glucuronide do not predict clinical observations in cancer patients. Palliat Med 17 8 (2003) 679-687
8. Shafer S.L., and Varvel J.R. Pharmacokinetics, pharmacodynamics, and rational opioid selection. Anesthesiology 74 1 (1991) 53-63
9. Bouw M.R., Xie R., Tunblad K., and Hammarlund-Udenaes M. Blood-brain barrier transport and brain distribution of morphine-6-glucuronide in relation to the antinociceptive effect in rats-pharmacokinetic/pharmacodynamic modelling. Br J Pharmacol 134 8 (2001) 1796-1804
10. Tunblad K., Ederoth P., Gardenfors A., Hammarlund-Udenaes M., and Nordstrom C.H. Altered brain exposure of morphine in experimental meningitis studied with microdialysis. Acta Anaesthesiol Scand 48 3 (2004) 294-301
11. Cepeda M.S., Farrar J.T., Roa J.H., Boston R., Meng Q.C., Ruiz F., et al. Ethnicity influences morphine pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 70 4 (2001) 351-361
12. Zhou H.H., Sheller J.R., Nu H., Wood M., and Wood A.J. Ethnic differences in response to morphine. Clin Pharmacol Ther 54 5 (1993) 507-513
13. Mogil J.S. Pain genetics: pre- and post-genomic findings. International Association for the Study of Pain. Tech Corner IASP Newslett 2 (2000)
14. Indo Y., Tsuruta M., Hayashida Y., Karim M.A., Ohta K., Kawano T., et al. Mutations in the TRKA/NGF receptor gene in patients with congenital insensitivity to pain with anhidrosis. Nat Genet 13 4 (1996) 485-488
15. Sindrup S.H., Brosen K., Bjerring P., Arendt-Nielsen L., Larsen U., Angelo H.R., et al. Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine. Clin Pharmacol Ther 48 6 (1990) 686-693
16. Poulsen L., Arendt-Nielsen L., Brosen K., and Sindrup S.H. The hypoalgesic effect of tramadol in relation to CYP2D6. Clin Pharmacol Ther 60 6 (1996) 636-644
17. Stamer U.M., Lehnen K., Hothker F., Bayerer B., Wolf S., Hoeft A., et al. Impact of CYP2D6 genotype on postoperative tramadol analgesia. Pain 105 1/2 (2003) 231-238
18. Pasternak G.W., Bodnar R.J., Clark J.A., and Inturrisi C.E. Morphine-6-glucuronide, a potent mu agonist. Life Sci 41 26 (1987) 2845-2849
19. Coffman B.L., Rios G.R., King C.D., and Tephly T.R. Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Dispos 25 1 (1997) 1-4
20. Holthe M., Klepstad P., Zahlsen K., Borchgrevink P.C., Hagen L., Dale O., et al. Morphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1*28 polymorphisms in cancer patients on chronic morphine therapy. Eur J Clin Pharmacol 58 5 (2002) 353-356
21. Holthe M., Rakvag T.N., Klepstad P., Idle J.R., Kaasa S., Krokan H.E., et al. Sequence variations in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients. Pharmacogenomics J 3 1 (2003) 17-26 [Erratum in: Pharmacogenomics J 2003;3(4):248]
22. Sawyer M.B., Innocenti F., Das S., Cheng C., Ramirez J., Pantle-Fisher F.H., et al. A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine. Clin Pharmacol Ther 73 6 (2003) 566-574
23. Duguay Y., Baar C., Skorpen F., and Guillemette C. A novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with significant impact on promoter activity. Clin Pharmacol Ther 75 3 (2004) 223-233
24. Hoehe M.R., Kopke K., Wendel B., Rohde K., Flachmeier C., Kidd K.K., et al. Sequence variability and candidate gene analysis in complex disease: association of mu opioid receptor gene variation with substance dependence. Hum Mol Genet 9 19 (2000) 2895-2908
25. Befort K., Filliol D., Decaillot F.M., Gaveriaux-Ruff C., Hoehe M.R., and Kieffer B.L. A single nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signaling. J Biol Chem 276 5 (2001) 3130-3137
26. Lotsch J., Skarke C., Grosch S., Darimont J., Schmidt H., and Geisslinger G. The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine. Pharmacogenetics 12 1 (2002) 3-9
27. Skarke C., Darimont J., Schmidt H., Geisslinger G., and Lotsch J. Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers. Clin Pharmacol Ther 73 1 (2003) 107-121
28. Romberg R.R., Olofsen E., Bijl H., Taschner P.E., Teppema L.J., Sarton E.Y., et al. Polymorphism of mu-opioid receptor gene (OPRM1:c.118A>G) does not protect against opioid-induced respiratory depression despite reduced analgesic response. Anesthesiology 102 3 (2005) 522-530
29. Lotsch J., Zimmermann M., Darimont J., Marx C., Dudziak R., Skarke C., et al. Does the A118G polymorphism at the mu-opioid receptor gene protect against morphine-6-glucuronide toxicity?. Anesthesiology 97 4 (2002) 814-819
30. Klepstad P., Rakvag T.T., Kaasa S., Holthe M., Dale O., Borchgrevink P.C., et al. The 118 A>G polymorphism in the human micro-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand 48 10 (2004) 1232-1239
31. Caraco Y., Maroz Y., and Davidson E. Variability in alfentanil analgesia maybe attributed to polymorphism in the mu-opioid receptor gene (abstract). Clin Pharamacol Ther 69 (2001) 63
32. Chou W.Y., Yang L.C., Lu H.F., Ko J.Y., Wang C.H., Lin S.H., et al. Association of mu-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty. Acta Anaesthesiol Scand 50 7 (2006) 787-792
33. Lotsch J., Skarke C., Wieting J., Oertel B.G., Schmidt H., Brockmoller J., et al. Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action. Clin Pharmacol Ther 79 1 (2006) 72-89
34. Janicki P.K., Schuler G., Francis D., Bohr A., Gordin V., Jarzembowski T., et al. A genetic association study of the functional A118G polymorphism of the human mu-opioid receptor gene in patients with acute and chronic pain. Anesth Analg 103 4 (2006) 1011-1017
35. Coulbault L., Beaussier M., Verstuyft C., Weickmans H., Dubert L., Tregouet D., et al. Environmental and genetic factors associated with morphine response in the postoperative period. Clin Pharmacol Ther 79 4 (2006) 316-324
36. Pasternak G.W. Incomplete cross tolerance and multiple mu opioid peptide receptors. Trends Pharmacol Sci 22 2 (2001) 67-70
37. Rossi G.C., Leventhal L., Pan Y.X., Cole J., Su W., Bodnar R.J., et al. Antisense mapping of MOR-1 in rats: distinguishing between morphine and morphine-6beta-glucuronide antinociception. J Pharmacol Exp Ther 281 1 (1997) 109-114
38. Pan Y.X., Xu J., Mahurter L., Xu M., Gilbert A.K., and Pasternak G.W. Identification and characterization of two new human mu opioid receptor splice variants, hMOR-1O and hMOR-1X. Biochem Biophys Res Commun 301 4 (2003) 1057-1061
39. Thompson S.J., Koszdin K., and Bernards C.M. Opiate-induced analgesia is increased and prolonged in mice lacking P-glycoprotein. Anesthesiology 92 5 (2000) 1392-1399
40. Klepstad P., Dale O., Skorpen F., Borchgrevink P.C., and Kaasa S. Genetic variability and clinical efficacy of morphine. Acta Anaesthesiol Scand 49 7 (2005) 902-908
41. Ross J.R., Rutter D., Welsh K., Joel S.P., Goller K., Wells A.U., et al. Clinical response to morphine in cancer patients and genetic variation in candidate genes. Pharmacogenomics J 5 5 (2005) 324-336
42. Raehal K.M., Walker J.K., and Bohn L.M. Morphine side effects in beta-arrestin 2 knockout mice. J Pharmacol Exp Ther 314 3 (2005) 1195-1201
43. Niemi G., and Breivik H. The minimally effective concentration of adrenaline in a low-concentration thoracic epidural analgesic infusion of bupivacaine, fentanyl and adrenaline after major surgery. A randomized, double-blind, dose-finding study. Acta Anaesthesiol Scand 47 4 (2003) 439-450
44. Lotta T., Vidgren J., Tilgmann C., Ulmanen I., Melen K., Julkunen I., et al. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 34 13 (1995) 4202-4210
45. Zubieta J.K., Heitzeg M.M., Smith Y.R., Bueller J.A., Xu K., Xu Y., et al. COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science 299 5610 (2003) 1240-1243
46. Rakvag T.T., Klepstad P., Baar C., Kvam T.M., Dale O., Kaasa S., et al. The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain 116 1/2 (2005) 73-78
47. Mogil J.S., Ritchie J., Smith S.B., Strasburg K., Kaplan L., Wallace M.R., et al. Melanocortin-1 receptor gene variants affect pain and mu-opioid analgesia in mice and humans. J Med Genet 42 7 (2005) 583-587
48. Mogil J.S., Wilson S.G., Chesler E.J., Rankin A.L., Nemmani K.V., Lariviere W.R., et al. The melanocortin-1 receptor gene mediates female-specific mechanisms of analgesia in mice and humans. Proc Natl Acad Sci USA 100 8 (2003) 4867-4872